These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 22736030)

  • 1. A polyglutamine expansion disease protein sequesters PTIP to attenuate DNA repair and increase genomic instability.
    Xiao H; Yu Z; Wu Y; Nan J; Merry DE; Sekiguchi JM; Ferguson DO; Lieberman AP; Dressler GR
    Hum Mol Genet; 2012 Oct; 21(19):4225-36. PubMed ID: 22736030
    [TBL] [Abstract][Full Text] [Related]  

  • 2. X-Linked Spinal and Bulbar Muscular Atrophy: From Clinical Genetic Features and Molecular Pathology to Mechanisms Underlying Disease Toxicity.
    Cortes CJ; La Spada AR
    Adv Exp Med Biol; 2018; 1049():103-133. PubMed ID: 29427100
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In Vitro and In Vivo Modeling of Spinal and Bulbar Muscular Atrophy.
    Pennuto M; Basso M
    J Mol Neurosci; 2016 Mar; 58(3):365-73. PubMed ID: 26614347
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of the androgen receptor CAG repeat polymorphism in prostate cancer, and spinal and bulbar muscular atrophy.
    Kumar R; Atamna H; Zakharov MN; Bhasin S; Khan SH; Jasuja R
    Life Sci; 2011 Mar; 88(13-14):565-71. PubMed ID: 21284948
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proteasomal and autophagic degradative activities in spinal and bulbar muscular atrophy.
    Rusmini P; Bolzoni E; Crippa V; Onesto E; Sau D; Galbiati M; Piccolella M; Poletti A
    Neurobiol Dis; 2010 Nov; 40(2):361-9. PubMed ID: 20621188
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular pathophysiology and disease-modifying therapies for spinal and bulbar muscular atrophy.
    Katsuno M; Banno H; Suzuki K; Adachi H; Tanaka F; Sobue G
    Arch Neurol; 2012 Apr; 69(4):436-40. PubMed ID: 22158719
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A small-molecule Nrf1 and Nrf2 activator mitigates polyglutamine toxicity in spinal and bulbar muscular atrophy.
    Bott LC; Badders NM; Chen KL; Harmison GG; Bautista E; Shih CC; Katsuno M; Sobue G; Taylor JP; Dantuma NP; Fischbeck KH; Rinaldi C
    Hum Mol Genet; 2016 May; 25(10):1979-1989. PubMed ID: 26962150
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiandrogen flutamide protects male mice from androgen-dependent toxicity in three models of spinal bulbar muscular atrophy.
    Renier KJ; Troxell-Smith SM; Johansen JA; Katsuno M; Adachi H; Sobue G; Chua JP; Sun Kim H; Lieberman AP; Breedlove SM; Jordan CL
    Endocrinology; 2014 Jul; 155(7):2624-34. PubMed ID: 24742193
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of the Androgen Receptor by Antiandrogens in Spinobulbar Muscle Atrophy.
    Baniahmad A
    J Mol Neurosci; 2016 Mar; 58(3):343-7. PubMed ID: 26563449
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An interdomain interaction of the androgen receptor is required for its aggregation and toxicity in spinal and bulbar muscular atrophy.
    Orr CR; Montie HL; Liu Y; Bolzoni E; Jenkins SC; Wilson EM; Joseph JD; McDonnell DP; Merry DE
    J Biol Chem; 2010 Nov; 285(46):35567-77. PubMed ID: 20826791
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular Mechanisms and Therapeutics for SBMA/Kennedy's Disease.
    Arnold FJ; Merry DE
    Neurotherapeutics; 2019 Oct; 16(4):928-947. PubMed ID: 31686397
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of androgen receptor polyQ chain elongation in Kennedy's disease and use of natural osmolytes as potential therapeutic targets.
    Kumar R
    IUBMB Life; 2012 Nov; 64(11):879-84. PubMed ID: 23024039
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Role of the Protein Quality Control System in SBMA.
    Rusmini P; Crippa V; Cristofani R; Rinaldi C; Cicardi ME; Galbiati M; Carra S; Malik B; Greensmith L; Poletti A
    J Mol Neurosci; 2016 Mar; 58(3):348-64. PubMed ID: 26572535
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Molecular-targeted therapies for spinal and bulbar muscular atrophy].
    Katsuno M; Banno H; Suzuki K; Adachi H; Tanaka F; Sobue G
    Rinsho Shinkeigaku; 2009 Nov; 49(11):917-20. PubMed ID: 20030248
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deubiquitinase USP7 contributes to the pathogenicity of spinal and bulbar muscular atrophy.
    Pluciennik A; Liu Y; Molotsky E; Marsh GB; Ranxhi B; Arnold FJ; St-Cyr S; Davidson B; Pourshafie N; Lieberman AP; Gu W; Todi SV; Merry DE
    J Clin Invest; 2021 Jan; 131(1):. PubMed ID: 33170804
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular pathogenesis of spinal bulbar muscular atrophy (Kennedy's disease) and avenues for treatment.
    Grunseich C; Fischbeck KH
    Curr Opin Neurol; 2020 Oct; 33(5):629-634. PubMed ID: 32773451
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Triplet repeat disease, with particular emphasis of spinal and bulbar muscular atrophy (SBMA)].
    Sobue G
    Rinsho Shinkeigaku; 2000 Dec; 40(12):1193-5. PubMed ID: 11464455
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytoplasmic retention of polyglutamine-expanded androgen receptor ameliorates disease via autophagy in a mouse model of spinal and bulbar muscular atrophy.
    Montie HL; Cho MS; Holder L; Liu Y; Tsvetkov AS; Finkbeiner S; Merry DE
    Hum Mol Genet; 2009 Jun; 18(11):1937-50. PubMed ID: 19279159
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New routes to therapy for spinal and bulbar muscular atrophy.
    Rocchi A; Pennuto M
    J Mol Neurosci; 2013 Jul; 50(3):514-23. PubMed ID: 23420040
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impaired Nuclear Export of Polyglutamine-Expanded Androgen Receptor in Spinal and Bulbar Muscular Atrophy.
    Arnold FJ; Pluciennik A; Merry DE
    Sci Rep; 2019 Jan; 9(1):119. PubMed ID: 30644418
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.